For example, targeting the pro-fibrotic function of CAFs with Pirfenidone (PFD—an anti-fibrotic agent as well as a TGF–β antagonist) was shown to be efficient in combination with doxorubicin in a mouse model of triple-negative breast cancer (4T1) (129). Here, TGFB1 is linked to triple-negative breast carcinoma.